{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s)', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', \"Refer to Investigator's\", 'Brochure for', \"Investigator's\", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', '29']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Mobile spirometers (MicroDiary, manufactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', \"A participant will be withdrawn if the participant's treatment code is unblinded by the\", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', \"GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the\", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', \"report, identifying the participant's treatment assignment, may be sent to investigators in\", 'accordance with local regulations and/or GSK policy.', '30']\n\n###\n\n", "completion": "END"}